Credo (CRDO) Q4 2026 Earnings Transcript

Credo reported fiscal 2026 revenue of $1.3 billion, up 206% year over year, with Q4 revenue of $437 million and non-GAAP EPS of $3.46 for the year, highlighting major AI-driven demand and operating leverage. Management guided Q1 fiscal 2027 revenue to $465 million-$475 million and said full-year revenue should grow more than 80%, with optical revenue expected to exceed $600 million and each of DSPs, silicon photonics PICs, and ZeroFlap optics topping $100 million. The recent Dust Photonics acquisition expands the optical portfolio, while supply-chain tightness and a $750 million cash outflow in Q1 are the main execution considerations.

Analysis

CRDO’s real signal is not just growth, but the mix shift: management is telegraphing a second derivative inflection where optical becomes the marginal driver while copper remains the cash engine. That matters because the market tends to underwrite early-cycle optics as a multiple story, but here it is arriving with unusually high gross margin durability and operating leverage, which reduces the odds of a “growth at any cost” reset. The combination of strong FCF, a large cash buffer, and limited capex needs also means the company can self-fund multiple product ramps without balance-sheet stress, a meaningful advantage versus smaller interconnect peers.

The more interesting second-order effect is supply-chain power. By pre-committing capacity across several process nodes and owning more of the BOM through silicon photonics, CRDO is effectively converting vendor scarcity into a moat: competitors will likely be forced to ration launches or accept weaker economics just as 200G/lane and 1.6T transitions begin. That should pressure merchant DSP and module vendors with less vertical integration, while also creating a choke point for hyperscalers and neo-clouds that need reliability at scale; in other words, CRDO is becoming less a component supplier and more an allocation gatekeeper.

The key contrarian risk is that the market may be extrapolating the optical ramp too cleanly into fiscal 2027. Management itself implies the real step-up is second half weighted, so near-term numbers can still look merely “good,” and any delay in customer qualification, packaging yield, or 3nm availability would push the growth curve right by 1-2 quarters. Customer concentration remains a structural overhang: even if diversification improves, the revenue base is still exposed to a handful of procurement calendars, so a single hyperscaler pause can compress the multiple faster than the underlying demand thesis can rebuild it.

From a portfolio perspective, the cleanest expression is to own CRDO on pullbacks and pair it against a slower-moving interconnect or analog supplier that lacks product breadth and supply assurance. The asymmetric trade is that CRDO can rerate on confirmation of the second-half optical inflection, while the downside is partly cushioned by copper AEC resilience and FCF. The bear case needs a catalyst, not just valuation; absent a ramp slip, the stock likely remains in a positive revision cycle.

Key Decisions for Investors

• Long CRDO on a 2-4 week post-earnings consolidation, targeting the next revision cycle into the first half guide; use a stop if management commentary turns from 'capacity secured' to 'qualification delayed.'
• Buy CRDO Jan-2027 call spreads to express the second-half optical inflection with defined risk; the setup favors convexity because the market is underappreciating the mix shift and operating leverage.
• Pair trade: long CRDO / short a weaker networking or optical component peer with less vertical integration and thinner gross margins; thesis is that supply assurance and telemetry/software attach will win share in the 12-18 month window.
• Avoid chasing immediately after the print; wait for any fade from concentration-risk headlines or temporary guidance skepticism, since the better entry is likely before second-half optical orders get visible.
• Monitor customer-concentration and 3nm capacity indicators over the next 1-2 quarters; if either worsens, de-risk quickly because the stock’s multiple is likely priced for uninterrupted execution.